On Tuesday, Dr. Reddy’s Laboratories (DRL) stock jumped after the company announced the availability of a generic version of Nexavar pills in the United States. The medicine, also known as Sorafenib, is used to treat specific types of cancers of the liver, kidneys, and thyroid.
According to a regulatory filing, the US Food and Drug Administration (FDA) approved the company’s introduction of Dr Reddy’s Sorafenib
tablets, USP 200 mg.
On the BSE, the DRL stock rose by Rs54, or 1.3%, to Rs4,322.2 a share. The growth in DRL stock occurred amid violent market swings, as investors remained wary about the effects of soaring prices and the global economy.
Dr. Reddy’s Sorafenib pills come in bottles with a 120-count. In a market worth $70 million for the medicine, analysts foresee little competition.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
